Search

Your search keyword '"Nassi, L."' showing total 11 results
Start Over Author "Nassi, L." Publisher wiley
11 results on '"Nassi, L."'

1. Primary Mediastinal B‐cell Lymphoma, a nationwide real‐life retrospective study from Fondazione Italiana Linfomi (FIL)

Author

Iannitto, E., primary, Balzarotti, M., additional, Martelli, M., additional, Zinzani, P., additional, Tucci, A., additional, Di Rocco, A., additional, Cavallo, F., additional, Usai, S. V., additional, Guidetti, A., additional, Ravano, E., additional, Merli, F., additional, Botto, B., additional, Pelosini, M., additional, Tecchio, C., additional, Spina, M., additional, Derenzini, E., additional, Finotto, S., additional, Mola, B., additional, Pinto, A., additional, Zanni, E., additional, Battistini, R., additional, Hohaus, S., additional, Dogliotti, I., additional, Gini, G., additional, Zilioli, V. R., additional, De Lorenzo, S., additional, Dodero, A., additional, Broccoli, A., additional, Maggi, A., additional, Mannarella, C., additional, Chiarenza, A., additional, Pastore, D., additional, Cascavilla, N., additional, Musto, P., additional, Stelitano, C., additional, Di Raimondo, F., additional, Di Renzo, N., additional, Liberati, A. M., additional, Salerno, M., additional, Scalone, R., additional, Nassi, L., additional, Patti, C., additional, Polizzi, V., additional, Guarini, A., additional, Amato, G., additional, Ciccone, G., additional, Evangelista, A., additional, Lo Presti, F., additional, La Porta, A., additional, Mannina, D., additional, Calogero, R. D., additional, Musso, M., additional, and Consoli, U., additional

Published
2023
Full Text
View/download PDF

2. P1208: CHARACTERISTICS AND CLINICAL OUTCOMES OF PATIENTS WITH ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA: REPORT FROM THE PROSPECTIVE INTERNATIONAL T-CELL LYMPHOMA PROJECT

Author

Chiattone, C., primary, Civallero, M., additional, Fischer, T., additional, Miranda, E., additional, Manni, M., additional, Zing, N. P. C., additional, Pileri, S. A., additional, Montoto, S., additional, Horwitz, S. M., additional, Cabrera, M. E., additional, De Souza, C. A., additional, Nagler, A., additional, Luminari, S., additional, Ferreri, A. J. M., additional, Carson, K. R., additional, Re, A., additional, Rigacci, L., additional, Nassi, L., additional, Federico, M., additional, and Inghirami, G., additional

Published
2022
Full Text
View/download PDF

3. THE ELDERLY PROGNOSTIC INDEX (EPI) PREDICTS EARLY MORTALITY IN OLDER PATIENTS WITH DLBCL. A SUBSTUDY OF THE ELDERLY PROJECT BY THE FONDAZIONE ITALIANA LINFOMI (FIL)

Author

Merli, F., primary, Tucci, A., additional, Arcari, A., additional, Rigacci, L., additional, Cavallo, F., additional, Cabras, G., additional, Alvarez, I., additional, Fabbri, A., additional, Re, A., additional, Ferrero, S., additional, Puccini, B., additional, Usai, S. V., additional, Ferrari, A., additional, Cencini, E., additional, Pennese, E., additional, Zilioli, V. R., additional, Marino, D., additional, Balzarotti, M., additional, Cox, M. C., additional, Zanni, M., additional, Rocco, A., additional, Lleshi, A., additional, Botto, B., additional, Hohaus, S., additional, Merli, M., additional, Sartori, R., additional, Gini, G., additional, Nassi, L., additional, Musuraca, G., additional, Tani, M., additional, Bottelli, C., additional, Kovalchuk, S., additional, Re, F., additional, Flenghi, L., additional, Molinari, A., additional, Tarantini, G., additional, Chimienti, E., additional, Marcheselli, L., additional, Mammi, C., additional, Luminari, S., additional, and Spina, M., additional

Published
2021
Full Text
View/download PDF

4. UPDATED RESULTS OF THE FIL “MIRO” STUDY, A MULTICENTER PHASE II TRIAL COMBINING LOCAL RADIOTHERAPY AND MRD‐DRIVEN IMMUNOTHERAPY IN EARLY‐STAGE FOLLICULAR LYMPHOMA

Author

Pulsoni, A., primary, Tosti, M. E., additional, Ferrero, S., additional, Luminari, S., additional, Dondi, A., additional, Liberati, A. M., additional, Cenfra, N., additional, Renzi, D., additional, Zanni, M., additional, Boccomini, C., additional, Ferreri, A. J., additional, Rattotti, S., additional, Zilioli, V. R., additional, Bernuzzi, P., additional, Bolis, S., additional, Musuraca, G., additional, Nassi, L., additional, Perrone, T., additional, Stelitano, C., additional, Anastasia, A., additional, Corradini, P., additional, Partesotti, G., additional, Re, F., additional, Cencini, E., additional, Mannarella, C., additional, Mannina, D., additional, Molinari, A. L., additional, Tani, M., additional, Annechini, G., additional, Assanto, G. M., additional, Grapulin, L., additional, Guarini, A., additional, Cavalli, M., additional, De Novi, L. A., additional, Ciabatti, E., additional, Mantoan, B., additional, Della Starza, I., additional, Arcaini, L., additional, Ricardi, U., additional, Gattei, V., additional, Galimberti, S., additional, Ladetto, M., additional, Foà, R., additional, and Del Giudice, I., additional

Published
2021
Full Text
View/download PDF

5. LATE TOXICITIES AND LONG‐TERM MONITORING IN CLASSICAL HODGKIN LYMPHOMA AND DIFFUSE LARGE B‐CELL LYMPHOMA SURVIVORS: A SERIES OF SYSTEMATIC REVIEWS OF THE FONDAZIONE ITALIANA LINFOMI

Author

Minoia, C., primary, Gerardi, C., additional, Allocati, E., additional, De Sanctis, V., additional, Franceschetti, S., additional, Viviani, S., additional, Annunziata, M. A., additional, Bari, A., additional, Skrypets, T., additional, Oliva, S., additional, Puzzovivo, A., additional, Di Molfetta, S., additional, Caccavari, V., additional, Di Russo, A., additional, Loseto, G., additional, Daniele, A., additional, Nassi, L., additional, Gini, G., additional, and Guarini, A., additional

Published
2021
Full Text
View/download PDF

6. OUTCOMES IN FIRST RELAPSED-REFRACTORY YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE MANTLE-FIRST STUDY

Author

Visco, C., primary, Di Rocco, A., additional, Tisi, M.C., additional, Morello, L., additional, Evangelista, A., additional, Zilioli, V.R., additional, Rusconi, C., additional, Hohaus, S., additional, Sciarra, R., additional, Re, A., additional, Tecchio, C., additional, Chiappella, A., additional, Marin-Niebla, A., additional, McCulloch, R., additional, Gini, G., additional, Perrone, T., additional, Nassi, L., additional, Pennese, E., additional, Stefani, P.M., additional, Cox, M.C., additional, Bozzoli, V., additional, Fabbri, A., additional, Polli, V., additional, Ferrero, S., additional, De Celis, I.A., additional, Sica, A., additional, Arcaini, L., additional, Balzarotti, M., additional, Rule, S., additional, and Vitolo, U., additional

Published
2019
Full Text
View/download PDF

7. THE ELDERLY PROJECT BY THE FONDAZIONE ITALIANA LINFOMI: A PROSPECTIVE COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) OF 1353 ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

Author

Spina, M., primary, Merli, F., additional, Puccini, B., additional, Cavallo, F., additional, Cabras, M.G., additional, Fabbri, A., additional, Angrilli, F., additional, Zilioli, V.R., additional, Marino, D., additional, Balzarotti, M., additional, Ladetto, M., additional, Cox, M.C., additional, Petrucci, L., additional, Arcari, A., additional, Gini, G., additional, Chiappella, A., additional, Hohaus, S., additional, Musuraca, G., additional, Merli, M., additional, Sartori, R., additional, Nassi, L., additional, Tani, M., additional, Re, F., additional, Flenghi, L., additional, Molinari, A., additional, Kovalchuk, S., additional, Bottelli, C., additional, Ferrero, S., additional, Dessì, D., additional, Cencini, E., additional, Pennese, E., additional, Marcheselli, L., additional, Mammi, C., additional, Luminari, S., additional, and Tucci, A., additional

Published
2019
Full Text
View/download PDF

8. RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI.

Author

Federico, M., primary, Mannina, D., additional, Versari, A., additional, Ferrero, S., additional, Marcheselli, L., additional, Boccomini, C., additional, Dondi, A., additional, Tucci, A., additional, Guerra, L., additional, Galimberti, S., additional, Cavallo, F., additional, Olivieri, J., additional, Corradini, P., additional, Arcaini, L., additional, Chauvie, S., additional, Del Giudice, I., additional, Rusconi, C., additional, Pinto, A., additional, Molinari, A., additional, Pulsoni, A., additional, Merli, M., additional, Kovalchuk, S., additional, Nassi, L., additional, Bolis, S., additional, Gattei, V., additional, Manni, M., additional, Pileri, S., additional, Brugiatelli, M., additional, and Luminari, S., additional

Published
2019
Full Text
View/download PDF

9. PHASE II FIL-PTCL13 STUDY OF ROMIDEPSIN-CHOEP FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND TRANSPLANTATION IN UNTREATED PERIPHERAL T-CELL LYMPHOMAS

Author

Chiappella, A., primary, Carniti, C., additional, Evangelista, A., additional, Re, A., additional, Cabras, M.G., additional, Stefoni, V., additional, Castellino, C., additional, Congiu, A.G., additional, Pinto, A., additional, Zanni, M., additional, Rusconi, C., additional, Molinari, A.L., additional, Ciancia, R., additional, Baldini, L., additional, Nassi, L., additional, Re, F., additional, Tani, M., additional, Ilariucci, F., additional, Cavallo, F., additional, Santoro, A., additional, Volpetti, S., additional, Dodero, A., additional, Pileri, S.A., additional, Ciccone, G., additional, and Corradini, P., additional

Published
2019
Full Text
View/download PDF

10. Association of Juvenile Dermatomyositis Disease Activity With the Expansion of Blood Memory B and T Cell Subsets Lacking Follicular Markers.

Author

Gofshteyn JS, Mansfield L, Spitznagle J, Balasubramanian P, Cardenas J, Miller T, Gu J, Wang X, Punaro M, Fuller J, Nassi L, Stewart K, Ohouo M, Stagnar C, Baisch J, Walters L, Wang Y, Yan H, Rinchai D, Chaussabel D, Caielli S, Hong S, Onel K, Wright T, and Pascual V

Subjects
Humans, Leukocytes, Mononuclear, T-Lymphocytes, Helper-Inducer metabolism, CD4-Positive T-Lymphocytes metabolism, Aldehyde-Lyases metabolism, Dermatomyositis metabolism
Abstract

Objective: This study was undertaken to identify blood markers of juvenile dermatomyositis (DM) disease activity (DA), which are needed to improve disease management., Methods: The study comprised a total of 123 juvenile DM patients and 53 healthy controls. Results of laboratory tests (aldolase, creatinine kinase, lactate dehydrogenase [LDH], aspartate aminotransferase) and clinical measures of DA in patients with juvenile DM, including the Manual Muscle Testing in 8 muscles (MMT-8), Childhood Myositis Assessment Scale (CMAS), and disease activity scores (DAS) (total DAS for juvenile DM, the muscle DAS, and the skin DAS), were recorded when available. Surface phenotype of peripheral blood mononuclear cells was assessed using flow cytometry. Whole blood transcriptional profiles were studied using either RNA-sequencing or microarrays. Differential gene expression was determined using DESeq and compared by pathway and gene ontology analyses., Results: Conventional memory (CD27+IgD-) B cells expressing low CXCR5 levels (CXCR5 low/- CM B cells) were significantly increased in frequency and absolute numbers in 2 independent cohorts of juvenile DM patients compared with healthy controls. The frequency of CD4+ Th2 memory cells (CD45RA-CXCR5-CCR6-CXCR3-) was also increased in juvenile DM, especially in patients who were within <1 year from diagnosis. The frequency of CXCR5 low/- CM B cells correlated with serum aldolase levels and with a blood interferon-stimulated gene transcriptional signature. Furthermore, both the frequency and absolute numbers of CXCR5 low/- CM B cells correlated with clinical and laboratory measures of muscle DA (MMT-8, CMAS, aldolase, and LDH)., Conclusion: These findings suggest that both CM B cells lacking the CXCR5 follicular marker and CXCR5- Th2 cells represent potential biomarkers of DA in juvenile DM and may contribute to its pathogenesis., (© 2023 American College of Rheumatology.)

Published
2023
Full Text
View/download PDF

11. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.

Author

Rigacci L, Carrai V, Nassi L, Alterini R, Longo G, Bernardi F, and Bosi A

Subjects
Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols toxicity, Carmustine administration & dosage, Cyclophosphamide administration & dosage, Cytarabine administration & dosage, Disease-Free Survival, Doxorubicin administration & dosage, Drug Administration Schedule, Etoposide administration & dosage, Female, Follow-Up Studies, Humans, Leucovorin administration & dosage, Lymphoma, Non-Hodgkin, Male, Methotrexate administration & dosage, Middle Aged, Mitoxantrone administration & dosage, Survival Rate, Vincristine administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use
Abstract

Background: The standard treatment for patients with aggressive non-Hodgkin lymphoma (NHL) is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Since 1989, the authors have used a new chemotherapy regimen with combined carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor called BAVEC-MiMA. The objective of the current study was to explore, after a long follow-up period, the impact of this third-generation regimen for the treatment of aggressive NHL., Methods: One hundred and one consecutive patients (median age, 41 years) with either B-cell (n=94 patients) or non-B-cell (n=7 patients), aggressive lymphoma were diagnosed and treated between 1989 and 1999 with the BAVEC-MiMA regimen., Results: The complete response rate was 74%, and the overall response rate was 89%. Eleven patients with refractory disease died rapidly after a median period of 5 months. The major toxicity was Grade 4 neutropenia (according to World Health Organization criteria), which was observed in 15 patients (15%). There were four toxicity-related deaths. The overall survival rate was 63% at 9 years. In multivariate analysis, factors that were associated with advantage in overall survival were response to induction therapy, bulky disease, and high score on the International Prognostic Index (IPI). The disease-free survival rate was 77% at 9 years. In multivariate analysis, the IPI was the most important variable for the definition of disease-free survival., Conclusions: The BAVEC-MiMA regimen was feasible on an outpatient basis, it was tolerated well, and it showed a low toxicity-related mortality. The long follow-up in patients with NHL, which is a rapidly fatal disease, led the authors to observe that, with this regimen, a cure was obtained in > 50% of patients who had low-risk or low-to-intermediate-risk, aggressive NHL., (2005 American Cancer Society.)

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results